Evidence map›Paper›PMID 41862440›Full record

ArticleCell death & disease2026

Fatty acid oxidation drives acetyl-CoA-dependent H3K9ac reprogramming to promote adaptive resistance to BRAF

Xumeng Wang, Jing Zhang, Jimeng Yuan, Liping Wen, Tianxing Ying, Zehang Xu, Zheng Zhou, Shitu Chen, Quan Zhou, Jinghao Sheng and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xumeng Wang *Department of Surgical Oncology of The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID http://orcid.org/0000-0003-4785-3900
Jing Zhang *Department of Surgical Oncology of The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jimeng YuanDepartment of Surgical Oncology of The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Liping WenDepartment of Surgical Oncology of The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Tianxing YingDepartment of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, China.
Zehang XuDepartment of Surgical Oncology of The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zheng ZhouDepartment of Surgical Oncology of The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Shitu ChenDepartment of Surgical Oncology of The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Quan ZhouDepartment of Surgical Oncology of The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jinghao ShengZhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou, China.ORCID http://orcid.org/0000-0002-1207-7449
Chi LuoLiangzhu Laboratory, Zhejiang University, Hangzhou, China. Chi.Luo@alumni.tufts.edu.
Lisong TengDepartment of Surgical Oncology of The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. lsteng@zju.edu.cn.ORCID http://orcid.org/0000-0001-6470-9017
Weibin WangDepartment of Surgical Oncology of The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. wbwang@zju.edu.cn.ORCID http://orcid.org/0000-0002-1303-5486

Funding

National Natural Science Foundation of China (National Science Foundation of China) No. 81972495
6 · The paper itself

Abstract

BRAF-targeted therapy is a promising strategy for thyroid cancer. However, its efficacy is limited by drug resistance. This study elucidates the role of fatty acid oxidation (FAO) in mediating adaptive resistance to BRAF

Indexed as

Acetyl Coenzyme ADrug Resistance, NeoplasmFatty AcidsHistonesProto-Oncogene Proteins B-rafThyroid NeoplasmsAcetylationAnimalsCell Line, TumorCell MovementCell ProliferationHumansMetabolic ReprogrammingOxidation-ReductionProtein Kinase InhibitorsVemurafenibAcetyl Coenzyme ABRAF protein, humanFatty AcidsHistonesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafVemurafenib

Identifiers

PMID41862440
PMCPMC13039272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.